{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:11:21Z","timestamp":1790611881195,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00415-025-13322-7","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:17:26Z","timestamp":1759760246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study"],"prefix":"10.1007","volume":"272","author":[{"given":"Rowaid","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Jackson-Tarlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Scott","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeela","family":"Nathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Oliver","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia F.","family":"Lucchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun H.","family":"Kantarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-935X","authenticated-orcid":false,"given":"B. Mark","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"13322_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378:169\u2013180","journal-title":"N Engl J Med"},{"key":"13322_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200064","author":"T Ziemssen","year":"2023","unstructured":"Ziemssen T, Bhan V, Chataway J et al (2023) Secondary progressive multiple sclerosis: a review of clinical characteristics, definition, prognostic tools, and disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200064","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13322_CR3","first-page":"540","volume":"78","author":"WF Schmalstieg","year":"2012","unstructured":"Schmalstieg WF, Keegan BM, Weinshenker BG (2012) Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. Neurol Ovid Technol (Wolters Kluwer Health) 78:540\u2013544","journal-title":"Neurol Ovid Technol (Wolters Kluwer Health)"},{"key":"13322_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1212\/WNL.0000000000003235","volume":"87","author":"BM Keegan","year":"2016","unstructured":"Keegan BM, Kaufmann TJ, Weinshenker BG et al (2016) Progressive solitary sclerosis: gradual motor impairment from a single CNS demyelinating lesion. Neurology 87:1713\u20131719","journal-title":"Neurology"},{"key":"13322_CR5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1177\/1352458518781979","volume":"24","author":"BM Keegan","year":"2018","unstructured":"Keegan BM, Kaufmann TJ, Weinshenker BG et al (2018) Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. Mult Scler 24:1445\u20131452","journal-title":"Mult Scler"},{"key":"13322_CR6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1177\/1352458520940983","volume":"27","author":"RM Kassa","year":"2021","unstructured":"Kassa RM, Sechi E, Flanagan EP et al (2021) Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Mult Scler 27:895\u2013902","journal-title":"Mult Scler"},{"key":"13322_CR7","first-page":"e628","volume":"93","author":"E Sechi","year":"2019","unstructured":"Sechi E, Keegan BM, Kaufmann TJ, Kantarci OH, Weinshenker BG, Flanagan EP (2019) Unilateral motor progression in MS: Association with a critical corticospinal tract lesion. Neurol Ovid Technol (Wolters Kluwer Health) 93:e628\u2013e634","journal-title":"Neurol Ovid Technol (Wolters Kluwer Health)"},{"key":"13322_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/13524585221114438","volume":"29","author":"CS Jackson-Tarlton","year":"2023","unstructured":"Jackson-Tarlton CS, Flanagan EP, Messina SA et al (2023) Progressive motor impairment from \u201ccritical\u201d demyelinating lesions of the cervicomedullary junction. Mult Scler 29:74\u201380","journal-title":"Mult Scler"},{"key":"13322_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.msard.2018.12.023","volume":"28","author":"MA Sahraian","year":"2019","unstructured":"Sahraian MA, Ghiasian M, Moghadasi AN, Shafaei M, Ghaffari M (2019) Progressive solitary sclerosis presented with diplopia: a case report. Mult Scler Relat Disord 28:129\u2013131","journal-title":"Mult Scler Relat Disord"},{"key":"13322_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40120-017-0082-8","volume":"6","author":"C Lebrun","year":"2017","unstructured":"Lebrun C, Cohen M, Mondot L, Ayrignac X, Labauge P (2017) A case report of solitary sclerosis: this is really multiple sclerosis. Neurol Ther. 6:259\u2013263","journal-title":"Neurol Ther."},{"key":"13322_CR11","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1177\/1352458514535129","volume":"20","author":"S Lattanzi","year":"2014","unstructured":"Lattanzi S, Logullo F, Di Bella P, Silvestrini M, Provinciali L (2014) Multiple sclerosis, solitary sclerosis or something else? Mult Scler 20:1819\u20131824","journal-title":"Mult Scler"},{"key":"13322_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1179\/2045772314Y.0000000283","volume":"38","author":"D Rathnasabapathi","year":"2015","unstructured":"Rathnasabapathi D, Elsone L, Krishnan A, Young C, Larner A, Jacob A (2015) Solitary sclerosis: progressive neurological deficit from a spatially isolated demyelinating lesion: a further report. J Spinal Cord Med 38:551\u2013555","journal-title":"J Spinal Cord Med"},{"key":"13322_CR13","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8304","author":"BM Keegan","year":"2024","unstructured":"Keegan BM, Messina SA, Hanson D et al (2024) Mr imaging features of critical spinal demyelinating lesions associated with progressive motor impairment. AJNR Am J Neuroradiol. https:\/\/doi.org\/10.3174\/ajnr.A8304","journal-title":"AJNR Am J Neuroradiol"},{"key":"13322_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007933","author":"EA Yeh","year":"2019","unstructured":"Yeh EA, Fox RJ (2019) Demyelinating lesions and progressive MS: location, location, location. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000007933","journal-title":"Neurology"},{"key":"13322_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"key":"13322_CR16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/archneurol.2009.190","volume":"66","author":"NP Staff","year":"2009","unstructured":"Staff NP, Lucchinetti CF, Keegan BM (2009) Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol 66:1139\u20131143","journal-title":"Arch Neurol"},{"key":"13322_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/1352458508101934","volume":"15","author":"VM Anderson","year":"2009","unstructured":"Anderson VM, Fisniku LK, Altmann DR, Thompson AJ, Miller DH (2009) MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Mult Scler 15:811\u2013817","journal-title":"Mult Scler"},{"key":"13322_CR18","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1093\/brain\/awad073","volume":"146","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay C, Okuda DT, Siva A et al (2023) The radiologically isolated syndrome: revised diagnostic criteria. Brain 146:3431\u20133443","journal-title":"Brain"},{"key":"13322_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol 22:268\u2013282","journal-title":"Lancet Neurol"},{"key":"13322_CR20","first-page":"177","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurol Ovid Technol (Wolters Kluwer Health) 85:177\u2013189","journal-title":"Neurol Ovid Technol (Wolters Kluwer Health)"},{"key":"13322_CR21","first-page":"1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol Ovid Technol (Wolters Kluwer Health) 33:1444\u20131452","journal-title":"Neurol Ovid Technol (Wolters Kluwer Health)"},{"key":"13322_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/1352458520929192","volume":"27","author":"E Sechi","year":"2021","unstructured":"Sechi E, Messina S, Keegan BM et al (2021) Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: a population-based case-control study. Mult Scler 27:667\u2013673","journal-title":"Mult Scler"},{"key":"13322_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/WNL.0000000000003542","volume":"88","author":"MA Rocca","year":"2017","unstructured":"Rocca MA, Battaglini M, Benedict RHB et al (2017) Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 88:403\u2013413","journal-title":"Neurology"},{"key":"13322_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.25150","volume":"83","author":"CJ Azevedo","year":"2018","unstructured":"Azevedo CJ, Cen SY, Khadka S et al (2018) Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol Wiley 83:223\u2013234","journal-title":"Ann Neurol Wiley"},{"key":"13322_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/13524585221141964","volume":"29","author":"A Calvi","year":"2023","unstructured":"Calvi A, Clarke MA, Prados F et al (2023) Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Mult Scler 29:352\u2013362","journal-title":"Mult Scler"},{"key":"13322_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS et al (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 20:653\u2013670","journal-title":"Lancet Neurol"},{"key":"13322_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.24564","volume":"79","author":"OH Kantarci","year":"2016","unstructured":"Kantarci OH, Lebrun C, Siva A et al (2016) Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann Neurol 79:288\u2013294","journal-title":"Ann Neurol"},{"key":"13322_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/1352458516663034","volume":"23","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Altmann DR, Alves Da Mota P et al (2017) Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler 23:665\u2013674","journal-title":"Mult Scler"},{"issue":"6","key":"13322_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/braincomms\/fcae395","volume":"6","author":"BM Keegan","year":"2024","unstructured":"Keegan BM, Absinta M, Cohen-Adad J et al (2024) Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future. Brain Commun. 6(6):395","journal-title":"Brain Commun."},{"key":"13322_CR30","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/brain\/awaa162","volume":"143","author":"A Kerbrat","year":"2020","unstructured":"Kerbrat A, Gros C, Badji A et al (2020) Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. Brain 143:2089\u20132105","journal-title":"Brain"},{"key":"13322_CR31","first-page":"1393","volume":"87","author":"AJ Solomon","year":"2016","unstructured":"Solomon AJ, Bourdette DN, Cross AH et al (2016) The contemporary spectrum of multiple sclerosis misdiagnosis. Neurol Ovid Technol (Wolters Kluwer Health) 87:1393\u20131399","journal-title":"Neurol Ovid Technol (Wolters Kluwer Health)"},{"key":"13322_CR32","first-page":"205521732110521","volume":"8","author":"B Barakat","year":"2022","unstructured":"Barakat B, Messina S, Nayak S et al (2022) Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Mult Scler J Exp Transl Clin 8:20552173211052160","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"13322_CR33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/1352458520948745","volume":"27","author":"S Nayak","year":"2021","unstructured":"Nayak S, Sechi E, Flanagan EP et al (2021) Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Mult Scler 27:1037\u20131045","journal-title":"Mult Scler"},{"key":"13322_CR34","doi-asserted-by":"publisher","first-page":"175628642110667","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Popescu V, Wuerfel J et al (2022) Smouldering multiple sclerosis: the \u201creal MS.\u201d Ther Adv Neurol Disord 15:17562864211066752","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13322-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13322-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:05:01Z","timestamp":1761699901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13322-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["13322"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13322-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rowaid Ahmad-nothing to disclose; Caitlin Jackson-Tarlton -speaking, consulting, and\/or advisory board participation for Novartis, Biogen, EMD Serono, Hoffmann La Roche, and Amgen Horizon unrelated to the current work; Eoin Flanagan-advisory boards for Alexion, Genentech, Horizon Therapeutics and UCB, research support from UCB, royalties from UpToDate, site principal investigator in a randomized clinical trial of Rozanolixizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by UCB, site principal investigator and a member of the steering committee for a clinical trial of satralizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by Roche\/Genentech, Co-Investigator on a study of ravulizumab for neuromyelitis optica spectrum disorder run by Alexion, has given educational talks on neuromyelitis optica spectrum disorder funded by Alexion, has received funding from the NIH (R01NS113828), honoraria for editing and writing articles for The Continuum Lifelong Learning in Neurology Journal, member of the medical advisory board of the MOG project and Sumaira Foundation, editorial board member of Neurology, Neuroimmunology and Neuroinflammation, The Journal of the Neurological Sciences and Neuroimmunology Reports, patent submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity; Steven Messina-nothing to disclose; W Scott Harmsen\u2014nothing to disclose; Tuba Chaudhry-nothing to disclose; Nabeela Nathoo\u2014nothing to disclose; W Oliver Tobin\u2014research funding from NIH and Mayo Clinic Center for MS and Autoimmune Neurology, book royalties from Oxford University Press; Michel Toledano \u2013 grant support from NINDS and serves on the Advisory Editorial Board of\n                      The\n                      Neurohospitalist. Sean Pittock -grant support from NINDS; Claudia Lucchinetti\u2014grant support from NIH and NINDS, Patent Number: US 11219402 Imaging biomarkers of neurologic disease, Patent Number: 7101679 NMO-IGG: marker autoantibody of neuromyelitis optica; Brian Weinshenker\u2014chair of attack adjudication committees for clinical trials in neuromyelitis optica spectrum disorders for Alexion, VielaBio\/Horizon Therapeutics, and UCB Biosciences, consulted with Genentech, Roche and CANbridge Pharmaceuticals regarding clinical trial designs for neuromyelitis optica spectrum disorders, speaking fees from Genentech, Horizon Therapeutics, Roche and Mitsubishi Tanabe, patent for NMO-IgG for diagnosis of neuromyelitis optica, royalties paid by Hospice Civil de Lyon, MVZ PD Dr. Volkmann und Kollegen GbR, Oxford University and RSR Limited; Orhun Kantarci\u2014research support from PCORI, UK MS Society, NMSS, NIAID, NINDS, book royalties Oxford University Press; B Mark Keegan\u2014consulting from Moderna, EMD Serono, Tr1X, Inc, book royalties Oxford University Press, philanthropic support from Mr. Ryan N. Lambert and Family.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"This study was approved by the Mayo Foundation Institutional Review Board (No. 09007045).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants included had consented to the use of their medical records for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"677"}}